Global X Genomics & Biotechnology ETF (GNOM)
| Assets | $143.89M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -19.01% |
| Volume | 155,141 |
| Open | 10.31 |
| Previous Close | 10.31 |
| Day's Range | 10.16 - 10.31 |
| 52-Week Low | 10.16 |
| 52-Week High | 14.36 |
| Beta | n/a |
| Holdings | 43 |
| Inception Date | Apr 5, 2019 |
About GNOM
Fund Home PageThe Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that is based on the Solactive Genomics index. The fund tracks an index of global biotech equities, selected and weighted by market cap. GNOM was launched on Apr 5, 2019 and is issued by Global X.
Top 10 Holdings
43.61% of assets| Name | Symbol | Weight |
|---|---|---|
| Sarepta Therapeutics, Inc. | SRPT | 5.18% |
| Genscript Biotech Corp Class H | 1548.HK | 4.56% |
| BioNTech SE | BNTX | 4.42% |
| Natera, Inc. | NTRA | 4.34% |
| CRISPR Therapeutics AG | CRSP | 4.33% |
| BioMarin Pharmaceutical Inc. | BMRN | 4.23% |
| Intellia Therapeutics, Inc. | NTLA | 4.23% |
| Pacific Biosciences of California, Inc. | PACB | 4.13% |
| Qiagen N.V. | QGEN | 4.12% |
| Veracyte, Inc. | VCYT | 4.09% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| 2021-12-30 | $0.00651 | 2022-01-07 |
| 2020-12-30 | $0.0324 | 2021-01-08 |
News
As Biotech Adjusts to “New Normal,” Get Exposure With This ETF
Biotechnology was a much sought-after sector following the pandemic, but it's been having to adjust to a new normal since. Still, the sector offers growth potential as new and innovative biotechnology...
ETF Battles: ARKG Vs IDNA Vs GNOM
Join us for a triple-header to determine the best genomics biotech ETF!
Snag Next-Generation Tech Exposure with This Genomics ETF
ETF investors looking to get in on the next generation of medical technology may want to give the Global X Genomics & Biotechnology ETF (GNOM) a closer look. Genomic sequencing is already playing a pi...
ETF Battles: ARKG Vs GNOM
Which biotech/genomics ETF is the better play?
Can Global X's GNOM Be the Next Big ETF?
Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.
Get On Board a Growing Biotech Industry With the GNOM ETF
It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over...
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%...
The Genomics Market is Poised for Growth Through 2025
Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-2...
Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says
Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.
Biotech ETFs Surge After Invitae Acquires ArcherDX
Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic info...
A Genomics ETF at the Center of the Coronavirus Fight
In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics ...
3 Genomics ETFs Worth Jumping For
The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliv...
Declining Costs Boost Allure of GNOM Genomics ETF
Declining costs are viewed as one of the biggest factors driving the genomics and data suggest those costs continue falling, a scenario that could benefit ETFs, such as the Global X Genomics & Biotech...
Why This Thematic Healthcare Could be a January Winner
Due in large part to the J.P. Morgan Health Care conference in San Francisco, the biotechnology industry’s marquee yearly confab, January is often a strong month for related equities and ETFs.
This High Growth ETF May Not Be As Pricey As You Think
When it comes to growth stocks, investors often expect they will pay up to access that.
A Young Biotech ETF With Plenty of Potential
The Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted earlier this year, making it one of the newest additions to the biotech ETFs fray, but despite its rookie status, GNOM is a fund with a...